WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, January 26, 2006

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,EPAB; PLUR=YES; OP=ADJ	
☐	L14	L13 and l1	3
☐	L13	l2 and l9	25
☐	L12	L11 and l2	2
☐	L11	L10 and l9	17
☐	L10	(424/130.1,141.1,155.1,617)![CCLS]	3435
☐	L9	(warrell or grant or brown).in.	42536
☐	L8	(warrell or grant or brwon).in.	8573
☐	L7	20020197256.pn.	1
☐	L6	L5 and L4	4
☐	L5	L1.clm.	129
☐	L4	L2.clm.	74
☐	L3	L2 and L1	134
☐	L2	gallium nitrate	1186
☐	L1	rituximab	1301

END OF SEARCH HISTORY

```
Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  DEC 05  CASREACT(R) - Over 10 million reactions available
 NEWS  4  DEC 14  2006 MeSH terms loaded in MEDLINE/LMEDLINE
 NEWS  5  DEC 14  2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER
 NEWS  6  DEC 14  CA/CAplus to be enhanced with updated IPC codes
 NEWS  7  DEC 21  IPC search and display fields enhanced in CA/CAplus with the
                  IPC reform
 NEWS  8  DEC 23  New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/
                  USPAT2
 NEWS  9  JAN 13  IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
 NEWS 10  JAN 13  New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to
                  INPADOC
 NEWS 11  JAN 17  Pre-1988 INPI data added to MARPAT
 NEWS 12  JAN 17  IPC 8 in the WPI family of databases including WPIFV

 NEWS EXPRESS  JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,
               CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
               V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT
               http://download.cas.org/express/v8.0-Discover/

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 07:05:09 ON 26 JAN 2006

=> file reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                 1.89       1.89

FILE 'REGISTRY' ENTERED AT 07:10:35 ON 26 JAN 2006
```

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 JAN 2006 HIGHEST RN 872575-89-8
DICTIONARY FILE UPDATES: 24 JAN 2006 HIGHEST RN 872575-89-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005.  A new display format, IDERL, is now    *
* available and contains the CA role and document type information. *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> E "GALLIUM NITRATE"/CN 25
E1            1     GALLIUM NIOBIUM ZINC OXIDE/CN
E2            1     GALLIUM NIOBIUM ZIRCONIUM OXIDE (GA4NB4ZRO18)/CN
E3            1 --> GALLIUM NITRATE/CN
E4            1     GALLIUM NITRATE (GA(NO3))/CN
E5            1     GALLIUM NITRATE (GA(NO3)3)/CN
E6            1     GALLIUM NITRATE NONAHYDRATE/CN
E7            1     GALLIUM NITRATE OXIDE (GA(NO3)O)/CN
E8            1     GALLIUM NITRATE OXIDE (GA(NO3)O), COMPD. WITH NITROGEN OXIDE
(N2O5) (2:1)/CN
E9            1     GALLIUM NITRIDE/CN
E10           1     GALLIUM NITRIDE (69GAN2)/CN
E11           1     GALLIUM NITRIDE (71GAN)/CN
E12           1     GALLIUM NITRIDE (71GAN2)/CN
E13           1     GALLIUM NITRIDE (GA0.45N0.55)/CN
E14           1     GALLIUM NITRIDE (GA0.52N0.48)/CN
E15           1     GALLIUM NITRIDE (GA0.61N0.39)/CN
E16           1     GALLIUM NITRIDE (GA0.62N0.38)/CN
E17           1     GALLIUM NITRIDE (GA0.6N0.4)/CN
E18           1     GALLIUM NITRIDE (GA0.7N)/CN
E19           1     GALLIUM NITRIDE (GA0.7N0.3)/CN
E20           1     GALLIUM NITRIDE (GA0.95N)/CN
E21           1     GALLIUM NITRIDE (GA1.04N)/CN
E22           1     GALLIUM NITRIDE (GA15N)/CN
E23           1     GALLIUM NITRIDE (GA2N)/CN
E24           1     GALLIUM NITRIDE (GA2N2)/CN
E25           1     GALLIUM NITRIDE (GA2N2), RADICAL ION(1-)/CN
```

```
=> S E3
L1            1 "GALLIUM NITRATE"/CN

=> DIS L1 1 SQIDE
THE ESTIMATED COST FOR THIS REQUEST IS 6.36 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   13494-90-1  REGISTRY
CN   Nitric acid, gallium salt (8CI, 9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Gallium nitrate (6CI, 7CI)
OTHER NAMES:
CN   Gallium nitrate (Ga(NO3)3)
CN   Gallium trinitrate
CN   Ganite
CN   NSC 15200
DR   27425-77-0, 33836-97-4, 39394-16-6
MF   Ga . 3 H N O3
CI   COM
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
       CSNB, DDFU, DIOGENES, DRUGU, EMBASE, GMELIN*, IFICDB, IFIPAT, IFIUDB,
       IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS,
       NIOSHTIC, PHAR, PIRA, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL, VTB
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, NDSL**, TSCA**
         (**Enter CHEMLIST File for up-to-date regulatory information)
DT.CA  CAplus document type:  Book; Conference; Dissertation; Journal; Patent;
       Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological study);
       OCCU (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties);
       RACT (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.P  Roles for non-specific derivatives from patents:  ANST (Analytical
       study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP
       (Properties); USES (Uses)
RL.NP  Roles from non-patents:  ANST (Analytical study); BIOL (Biological
       study); CMBI (Combinatorial study); MSC (Miscellaneous); OCCU
       (Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT
       (Reactant or reagent); USES (Uses); NORL (No role in record)
RLD.NP Roles for non-specific derivatives from non-patents:  ANST (Analytical
       study); PREP (Preparation); PRP (Properties); RACT (Reactant or reagent)
CRN  (7697-37-2)
```



```
●1/3  Ga

**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             718 REFERENCES IN FILE CA (1907 TO DATE)
              18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             722 REFERENCES IN FILE CAPLUS (1907 TO DATE)
               8 REFERENCES IN FILE CAOLD (PRIOR TO 1967)
```

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         7.54       9.43

FILE 'CAPLUS' ENTERED AT 07:11:39 ON 26 JAN 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 26 Jan 2006  VOL 144 ISS 5
FILE LAST UPDATED: 25 Jan 2006  (20060125/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l1
L2         723 L1

=> s antibod?
L3      452268 ANTIBOD?

=> s l2 (l) l3
L4           1 L2 (L) L3

=> d ibib 1

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1989:526604  CAPLUS
DOCUMENT NUMBER:          111:126604
TITLE:                    Combination iron depletion therapy
AUTHOR(S):                Taetle, Raymond; Honeysett, J. Michael; Bergeron,
                          Raymond
CORPORATE SOURCE:         Cancer Cent., Univ. California, San Diego, CA, USA
SOURCE:                   Journal of the National Cancer Institute (1989),
                          81(16), 1229-35
                          CODEN: JNCIEQ; ISSN: 0027-8874
DOCUMENT TYPE:            Journal
LANGUAGE:                 English


=> d ibib abs

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1989:526604  CAPLUS
DOCUMENT NUMBER:          111:126604
TITLE:                    Combination iron depletion therapy
AUTHOR(S):                Taetle, Raymond; Honeysett, J. Michael; Bergeron,
```

Raymond
CORPORATE SOURCE: Cancer Cent., Univ. California, San Diego, CA, USA
SOURCE: Journal of the National Cancer Institute (1989), 81(16), 1229-35
CODEN: JNCIEQ; ISSN: 0027-8874
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Iron (Fe) depletion with anti-transferrin (Tf) receptor monoclonal antibodies (MAbs), Fe chelators, or gallium (Ga) salts inhibits the growth of tumor cells. The cytotoxic effects of an IgA anti-human Tf receptor MAb, 42/6, combined with parabactin, a powerful Fe chelator, or Ga nitrate were studied in cell cultures. Parabactin inhibited in vitro growth of human hematopoietic and solid tumor cells, and the rank order of their sensitivities to the Fe chelator was identical to their relative sensitivity to MAb 42/6. When the most parabactin and MAb 42/6-sensitive (HL60 leukemia) and -resistant (KB carcinoma) cells were incubated with various concns. of parabactin, cell killing was time and dose dependent over the first 24 h. Little addnl. cytotoxicity occurred when cells were exposed to parabactin for 48 h. HL60 cells were slightly more sensitive than KB cells to parabactin cytotoxicity. Addition of anti-Tf receptor MAb 42/6 to parabactin increased cytotoxicity to HL60 cells over a narrow parabactin dose range but had little effect on cytotoxicity to KB cells. Cell cycle anal. of cells treated with parabactin for 24 h showed that doses causing variable cytotoxicity increased the percentage of cells in S phase, but higher parabactin concns. consistently arrested cells in G1 phase or at the G1/S interface. MAb 42/6 also increased toxicity of parabactin to granulocyte/macrophage colony-stimulating factors and normal marrow granulocyte/macrophage progenitors. When HL60 or KB cells were treated with MAb 42/6 combined with Ga nitrate, MAb 42/6 increased cytotoxicity of Ga for HL60 cells but had little or no effect on Ga cytotoxicity to KB cells. MAb 42/6 had minimal effects on cytotoxicity of the ribonucleotide reductase inhibitor isoquinaldehyde thiosemicarbazone to either HL60 or KB cells. Both hematopoietic and solid tumors were killed by Fe depletion, but the hematopoietic cells were more sensitive than solid tumor cells. Thus, the combined Fe depletion therapy with MAb 42/6 and Fe chelator or Ga salt increased toxicity to MAb 42/6-sensitive cells, such as HL60, but was not more effective against MAb 42/6-resistant solid tumor cells. Combination Fe depletion therapy of hematopoietic cell tumors merits evaluation in in vivo tumor systems.

```
=> s cancer? or tumor? or neoplas? or lymphom?
        281698 CANCER?
        415606 TUMOR?
        436247 NEOPLAS?
         35211 LYMPHOM?
L5      702822 CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?

=> s l5 and l2
L6         113 L5 AND L2

=> s l6 and l3
L7          17 L6 AND L3

=> s l17 not py>2002
L17 NOT FOUND
The L-number entered could not be found.  To see the definition
of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

=> s l7 not py>2002
       3474993 PY>2002
L8           9 L7 NOT PY>2002
```

```
=> s l8 and rituximab
          1238 RITUXIMAB
L9           0 L8 AND RITUXIMAB

=> d l8 ibib 1-4

L8   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2000:475560  CAPLUS
DOCUMENT NUMBER:          133:109949
TITLE:                    Pharmaceutical compositions for treatment of diseased
                          tissues
INVENTOR(S):              Lee, Clarence C.; Lee, Feng-Min
PATENT ASSIGNEE(S):       USA
SOURCE:                   PCT Int. Appl., 26 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2000040269         A2    20000713    WO 2000-US191           20000105
     WO 2000040269         A3    20001130
         W:  AU, CA, CN, JP
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
PRIORITY APPLN. INFO.:                        US 1999-114906P     P  19990105

L8   ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2000:227537  CAPLUS
DOCUMENT NUMBER:          132:262172
TITLE:                    Use of neoangiogenesis markers for diagnosis and
                          treatment of tumors
INVENTOR(S):              Krause, Werner; Muschick, Peter
PATENT ASSIGNEE(S):       Schering Aktiengesellschaft, Germany
SOURCE:                   PCT Int. Appl., 27 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 German
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2000018439         A2    20000406    WO 1999-EP7198          19990929
     WO 2000018439         A3    20000914
         W:  AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM,
             EE, ES, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR,
             KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ,
             VN, YU, ZA, ZW
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
     DE 19845798           A1    20000413    DE 1998-19845798        19980929
PRIORITY APPLN. INFO.:                        DE 1998-19845798    A   19980929

L8   ANSWER 3 OF 9  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         1999:736476  CAPLUS
DOCUMENT NUMBER:          131:346535
TITLE:                    Use of neomycin for treating angiogenesis-related
                          diseases
INVENTOR(S):              Hu, Guo-Fu; Vallee, Bert L.
```

PATENT ASSIGNEE(S): The Endowment for Research In Human Biology, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9958126	A1	19991118	WO 1999-US10269	19990511
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2331620	AA	19991118	CA 1999-2331620	19990511
AU 9939804	A1	19991129	AU 1999-39804	19990511
EP 1083896	A1	20010321	EP 1999-922915	19990511
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
US 6482802	B1	20021119	US 2000-700436	20001109
PRIORITY APPLN. INFO.:			US 1998-84921P P	19980511
			WO 1999-US10269 W	19990511

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1998:385263 CAPLUS
DOCUMENT NUMBER: 129:130935
TITLE: Transferrin receptor-dependent and -independent iron transport in gallium-resistant human lymphoid leukemic cells
AUTHOR(S): Chitambar, Christopher R.; Wereley, Janine P.
CORPORATE SOURCE: Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA
SOURCE: Blood (1998), 91(12), 4686-4693
CODEN: BLOOAW; ISSN: 0006-4971
PUBLISHER: W. B. Saunders Co.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l8 kwic 3

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AB . . . is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-**neoplastic** agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment. . .
IT Antitumor agents
(Wilms' **tumor**; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Kidney, **neoplasm**
(Wilms', inhibitors; neomycin, its analogs and other agents for

treatment of angiogenesis-related diseases)
IT Nerve, **neoplasm**
(acoustic neuroma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Skin, **neoplasm**
(basal cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Lung, **neoplasm**
(carcinoma; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Uterus, **neoplasm**
(cervix, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Intestine, **neoplasm**
(colon, carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Ovary, **neoplasm**
(cystadenocarcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Brain, **neoplasm**
(ependymoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Blood vessel, **neoplasm**
(hemangioma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Blood vessel, **neoplasm**
(hemangiosarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Liver, **neoplasm**
(hepatoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Ovary, **neoplasm**
Pancreas, **neoplasm**
Testis, **neoplasm**
(inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Adipose tissue, **neoplasm**
(liposarcoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Antitumor agents
(**lymphoma**; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Brain, **neoplasm**
Brain, **neoplasm**
(medulloblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT **Antibodies**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)
IT Angiogenic factors
Hepatocyte growth factor
Interleukin 8
Platelet-derived growth factors
Tumor necrosis factors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(neomycin and analogs are inhibitors of nuclear translocation of angiogenic factors for treatment of angiogenesis-related diseases)
IT Notochord
(**neoplasm**, chordoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Mammary gland
Prostate gland
Sweat gland
Sweat gland
(**neoplasm**, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Nerve, **neoplasm**
Nerve, **neoplasm**
(neuroblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Skin, **neoplasm**
(pseudoxanthoma elasticum; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Kidney, **neoplasm**
(renal cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Eye, **neoplasm**
(retinoblastoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Testis, **neoplasm**
(seminoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Lung, **neoplasm**
(small-cell carcinoma, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Antitumor agents
(synovial membrane **tumor** inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT Synovial membrane
(**tumors**, inhibitors; neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

IT 50-18-0, Cyclophosphamide 50-35-1, Thalidomide 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, Floxuridine 51-18-3, Triethylenemelamine 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 51-79-6, Urethane 52-24-4, Triethylenethiophosphoramide 52-67-5, D-Penicillamine 53-19-0, Mitotane 53-79-2, Puromycin 54-25-1, 6-Azauridine 54-91-1, Pipobroman 55-98-1, Busulfan 57-22-7, Vincristine 58-05-9, Folinic acid 58-19-5, Dromostanolone 59-05-2, Methotrexate 66-75-1, Uracil mustard 68-76-8, Triaziquone 69-33-0, Tubercidin 84-16-2, Hexestrol 89-38-3, Pteropterin 115-02-6, Azaserine 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 147-94-4, Cytarabine 148-82-3, Melphalan 151-56-4D, Aziridine, derivs., biological studies 154-42-7, Thioguanine 154-93-8, Carmustine 157-03-9, 6-Diazo-5-oxo-L-norleucine 302-22-7, Chlormadinone acetate 302-49-8, Uredepa 302-70-5, Mechlorethamine oxide hydrochloride 305-03-3, Chlorambucil 320-67-2, Azacitidine 362-07-2, 2-Methoxyestradiol 459-86-9, Mitoguazone 477-30-5, Demecolcine 488-41-5, Mitobronitol 494-03-1, Chlornaphazine 520-85-4, Medroxyprogesterone 522-40-7, Fosfestrol 545-55-1, Triethylenephosphoramide 555-77-1, 2,2',2''-Trichlorotriethylamine 566-48-3, Formestane 576-68-1, Mannomustine 595-33-5, Megestrol acetate 642-83-1, Aceglatone 645-05-6, Altretamine 801-52-5, Porfiromycin 865-21-4, Vinblastine 968-93-4, Testolactone 1402-44-4, Actinomycin F1 1404-00-8, Mitomycin 1404-15-5, Nogalamycin 1508-45-8, Podophyllinic acid 2-ethyl hydrazide 1661-29-6, Meturedepa 1936-40-9, Novembichin 1954-28-5, Etoglucid 1980-45-6, Benzodepa 2363-58-8, Epitiostanol 2608-24-4, Piposulfan 2998-57-4, Estramustine 3094-09-5, Doxifluridine 3546-10-9, Phenesterine 3733-81-1, Defosfamide 3778-73-2, Ifosfamide 3819-34-9, Phenamet 3930-19-6, Streptonigrin 4291-63-8, Cladribine 4342-03-4, Dacarbazine 4533-39-5, Nitracrine 4803-27-4, Anthramycin 5581-52-2, Thiamiprine 5633-18-1, Melengestrol 8052-16-2, Cactinomycin 9014-02-2, Zinostatin 9015-68-3, L-Asparaginase 9042-14-2, Dextran sulfate 10318-26-0,

Mitolactol 10540-29-1, Tamoxifen 11006-70-5, Olivomycin 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13425-98-4, Improsulfan **13494-90-1**, Gallium nitrate 13647-35-3, Trilostane 13665-88-8, Mopidamol 15663-27-1, Cisplatin 17021-26-0, Calusterone 17902-23-7, Tegafur 18378-89-7, Plicamycin 18883-66-4, Streptozocin 20830-81-3, Daunorubicin 21362-69-6, Mepitiostane 21416-67-1, Razoxane 21679-14-1, Fludarabine 22006-84-4, Denopterin 22089-22-1, Trofosfamide 23110-15-8, Fumagillin 23214-92-8, Doxorubicin 24279-91-2, Carboquone 24280-93-1, Mycophenolic acid 28014-46-2, Polyestradiol phosphate 29069-24-7, Prednimustine 29767-20-2, Teniposide 31698-14-3, Ancitabine 33069-62-4, Paclitaxel 33419-42-0, Etoposide 37270-94-3, Platelet factor 4 37339-90-5, Lentinan 41575-94-4, Carboplatin 41992-23-8, Spirogermanium 42471-28-3, Nimustine 50264-69-2, Lonidamine 50935-04-1, Carubicin 51264-14-3, Amsacrine 52128-35-5, Trimetrexate 53123-88-9, Rapamycin 53643-48-4, Vindesine 53714-56-0, Leuprolide 53910-25-1, Pentostatin 54083-22-6, Zorubicin 54749-90-5, Chlorozotocin 55726-47-1, Enocitabine 56420-45-2, Epirubicin 57773-63-4, Triptorelin 57982-77-1, Buserelin 57998-68-2, Diaziquone 58066-85-6, Miltefosine 58337-35-2, Elliptinium acetate 58957-92-9, Idarubicin 58970-76-6, Ubenimex 58994-96-0, Ranimustine 61163-28-8, β-1,3-Glucan sulfate 61422-45-5, Carmofur 61825-94-3, Oxaliplatin 62435-42-1, Perfosfamide 63612-50-0, Nilutamide 64431-69-2, Aclacinomycin S 65271-80-9, Mitoxanthrone 65646-68-6, Fenretinide 65807-02-5, Goserelin 68247-85-8, Peplomycin 70052-12-9, Eflornithine 70563-58-5, Herbimycin A 71628-96-1, Menogaril 72496-41-4, Pirarubicin 72732-56-0, Piritrexim 74913-06-7, Chromomycin 78186-34-2, Bisantrene 80576-83-6, Edatrexate 82413-20-5, Droloxifene 84088-42-6, Roquinimex 85622-93-1, Temozolomide 86090-08-6, Angiostatin 87806-31-3, Porfimer sodium 89149-10-0, 15-Deoxyspergualin 89778-26-7, Toremifene 90357-06-5, Bicalutamide 92118-27-9, Fotemustine 95058-81-4, Gemcitabine 98631-95-9, Sobuzoxane 99519-84-3, CAI 100286-90-6 102676-47-1, Fadrozole 103775-75-3, Miboplatin 106486-76-4, Carzinophilin 110690-43-2, Emitefur 112809-51-5, Letrozole 112887-68-0, Tomudex 114977-28-5, Docetaxel 120511-73-1, Anastrozole 123948-87-8, Topotecan 126509-46-4, Eponemycin 126595-07-1, Propagermanium 129298-91-5, AGM 1470 130370-60-4, Batimastat 142298-75-7, Ribonuclease inhibitor 154039-60-8, Marimastat 187888-07-9, Endostatin 188417-67-6, CM 101 196858-78-3 197850-48-9 197850-49-0 250331-65-8 250593-25-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neomycin, its analogs and other agents for treatment of angiogenesis-related diseases)

=> d 18 abs 3

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN

AB The present invention is directed to using neomycin or an analog thereof as a therapeutic agent to treat angiogenesis-related diseases, which are characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells. The present invention is also directed to pharmaceutical compns. comprising: (a) neomycin or an analog and, optionally, (b) another anti-angiogenic agent or an anti-**neoplastic** agent. The present invention is further directed to a method for screening neomycin analogs having anti-angiogenic activity. A preferred embodiment of the invention relates to using neomycin to treat subjects having such diseases. A dose of 20 ng neomycin/embryo or higher completely inhibited angiogenin-induced angiogenesis in the chorioallantoic membrane (CAM) assay. Neomycin inhibits angiogenin-induced angiogenesis mainly through inhibition of nuclear translocation of angiogenin.

```
=> file pctfull
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        28.84      38.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                        -2.25      -2.25

FILE 'PCTFULL' ENTERED AT 07:15:47 ON 26 JAN 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:          3 JAN 2006      <20060103/UP>
MOST RECENT UPDATE WEEK:       200552        <200552/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> UPDATING DELAYED DUE TO DELIVERY FORMAT CHANGES. <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
    USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHER
    DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION
    ABOUT THE IPC REFORM <<<

=> s gallium nitrate
         12196 GALLIUM
            17 GALLIUMS
         12203 GALLIUM
                 (GALLIUM OR GALLIUMS)
         31552 NITRATE
          8697 NITRATES
         36228 NITRATE
                 (NITRATE OR NITRATES)
L10        547 GALLIUM NITRATE
                 (GALLIUM(W)NITRATE)

=> s cancer? or tumor? or neoplas? or lymphom?
         74539 CANCER?
         62442 TUMOR?
         21534 NEOPLAS?
         17294 LYMPHOM?
L11      93747 CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?

=> s l10/clm
          3101 GALLIUM/CLM
          5022 NITRATE/CLM
L12         52 (GALLIUM NITRATE/CLM)
                 ((GALLIUM(W)NITRATE)/CLM)

=> s antibod?
L13      84196 ANTIBOD?

=> s l12 and l13
L14         28 L12 AND L13

=> s l14 and l11
L15         27 L14 AND L11

=> s rituximab
          1144 RITUXIMAB
```

```
            5 RITUXIMABS
L16        1144 RITUXIMAB
                (RITUXIMAB OR RITUXIMABS)

=> s l16 and l15
L17           6 L16 AND L15

=> s l13/clm
L18       32952 (ANTIBOD?/CLM)

=> s l18 and l12
L19          18 L18 AND L12

=> s l19 and l16
L20           3 L19 AND L16

=> d ibib 1-3

L20    ANSWER 1 OF 3     PCTFULL   COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER:        2005112973 PCTFULL  ED 20051206  EW 200548
TITLE (ENGLISH):         SENSITIZATION TO ANOTHER ANTICANCER THERAPY AND/OR
                         AMELIORATION OF A SIDE EFFECT OF ANOTHER ANTICANCER
                         THERAPY BY TREATMENT WITH A GST-ACTIVATED ANTICANCER
                         COMPOUND
TITLE (FRENCH):          SENSIBILISATION A UNE AUTRE THERAPIE ANTICANCEREUSE
                         ET/OU AMELIORATION D&#x2019;UN EFFET SECONDAIRE
                         D&#x2019;UNE AUTRE THERAPIE ANTICANCEREUSE A
                         L&#x2019;AIDE D&#x2019;UN TRAITEMENT IMPLIQUANT UN
                         COMPOSE ANTICANCEREUX ACTIVE PAR GST
INVENTOR(S):             BROWN, Gail, L., 2995 Woodside Road #400, Woodside,
                         California 94062, US [US, US];
                         KECK, James, G., 617 Harbor Colony Court, Redwood City,
                         California 94062, US [US, US];
                         WICK, Michael, M., 2995 Woodside Road #400, Woodside,
                         California 94062, US [US, US]
PATENT ASSIGNEE(S):      TELIK INC., 3165 Porter Drive, Palo Alto, California
                         94304, US [US, US], for all designates States except
                         US;
                         BROWN, Gail, L., 2995 Woodside Road #400, Woodside,
                         California 94062, US [US, US], for US only;
                         KECK, James, G., 617 Harbor Colony Court, Redwood City,
                         California 94062, US [US, US], for US only;
                         WICK, Michael, M., 2995 Woodside Road #400, Woodside,
                         California 94062, US [US, US], for US only
AGENT:                   ENG, Hugo M.$, Foley & Lardner LLP, 1530 Page Mill
                         Road, Palo Alto, California 94304$, US
LANGUAGE OF FILING:      English
LANGUAGE OF PUBL.:       English
DOCUMENT TYPE:           Patent
PATENT INFORMATION:
                         NUMBER              KIND     DATE
                         ---------------------------------
                         WO 2005112973         A1 20051201
DESIGNATED STATES
       W:                AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO
                         CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR
                         HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU
                         LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL
                         PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA
                         UG US UZ VC VN YU ZA ZM ZW
       RW (ARIPO):       BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW
       RW (EAPO):        AM AZ BY KG KZ MD RU TJ TM
       RW (EPO):         AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT
```

LT LU MC NL PL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2005-US17960 A 20050519
PRIORITY INFO.: US 2004-60/572,790 20040520

L20 ANSWER 2 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2004060317 PCTFULL ED 20040726 EW 200430
TITLE (ENGLISH): COMBINATION OF GALLIUM COMPOUNDS WITH NONCHEMOTHERAPEUTIC ANTICANCER AGENTS IN THE TREATMENT OF NEOPLASIA
TITLE (FRENCH): COMBINAISON DE COMPOSES A BASE DE GALLIUM ET D'AGENTS ANTICANCEREUX NON CHIMIOTHERAPEUTIQUES DESTINEE AU TRAITEMENT DE LA NEOPLASIE
INVENTOR(S): WARRELL, Raymond, P., Jr., 6 Kimball Circle, Westfield, NJ 07090, US [US, US];
GRANT, Stefan, C., 200 Wast 90th Street, Apartment 24-H, New York, NY 10128, US [US, US];
BROWN, Bob, D., 54 Leprechaun Drive, Long Hill Township, NJ 07946, US [US, US]
PATENT ASSIGNEE(S): GENTA INCORPORATED, Two Connell Drive, Berkeley Heights, NJ 07922, US [US, US], for all designates States except US;
WARRELL, Raymond, P., Jr., 6 Kimball Circle, Westfield, NJ 07090, US [US, US], for US only;
GRANT, Stefan, C., 200 Wast 90th Street, Apartment 24-H, New York, NY 10128, US [US, US], for US only;
BROWN, Bob, D., 54 Leprechaun Drive, Long Hill Township, NJ 07946, US [US, US], for US only
AGENT: BIRDE, Patrick, J.$, Kenyon and Kenyon, One Broadway, New York, NY 10004$, US
LANGUAGE OF FILING: English
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION:

NUMBER	KIND	DATE
WO 2004060317	A2	20040722

DESIGNATED STATES
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
RW (ARIPO): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO): AM AZ BY KG KZ MD RU TJ TM
RW (EPO): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI): BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
APPLICATION INFO.: WO 2003-US41746 A 20031231
PRIORITY INFO.: US 2002-60/437,275 20021231

L20 ANSWER 3 OF 3 PCTFULL COPYRIGHT 2006 Univentio on STN
ACCESSION NUMBER: 2004045593 PCTFULL ED 20040608 EW 200423
TITLE (ENGLISH): COMBINATION CANCER THERAPY WITH A GST-ACTIVATED ANTICANCER COMPOUND AND ANOTHER ANTICANCER THERAPY
TITLE (FRENCH): POLYTHERAPIE ANTICANCEREUSE AU MOYEN D'UN COMPOSE ANTICANCEREUX ACTIVE PAR GST ET D'UN AUTRE TRAITEMENT ANTICANCEREUX
INVENTOR(S): XU, Hua, 1567 Samedra Street, Sunnyvale, CA 94087, US;
BROWN, Gail, L., 2995 Woodside Road, #401, Woodside, CA 94062, US;
SCHOW, Steven, R., 204 Mendocino Way, Redwood City, CA 94065, US;

	KECK, James, G., 617 Harbor Colony Court, Redwood City, CA 94065, US
PATENT ASSIGNEE(S):	TELIK, INC., 3165 Porter Drive, Palo Alto, CA 94304, US [US, US]
AGENT:	NGUYEN, Sam, L.$, Heller, Ehrman White & McAuliffe LLP, 275 Middlefield Road, Menlo Park, CA 94025-3506$, US
LANGUAGE OF FILING:	English
LANGUAGE OF PUBL.:	English
DOCUMENT TYPE:	Patent
PATENT INFORMATION:	

NUMBER	KIND	DATE
WO 2004045593	A2	20040603

DESIGNATED STATES

W:	AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW
RW (ARIPO):	BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW
RW (EAPO):	AM AZ BY KG KZ MD RU TJ TM
RW (EPO):	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR
RW (OAPI):	BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

APPLICATION INFO.:	WO 2003-US36209	A 20031114
PRIORITY INFO.:	US 2002-60/426,983	20021115

=> d his

(FILE 'HOME' ENTERED AT 07:05:09 ON 26 JAN 2006)

FILE 'REGISTRY' ENTERED AT 07:10:35 ON 26 JAN 2006
E "GALLIUM NITRATE"/CN 25
L1 1 S E3

FILE 'CAPLUS' ENTERED AT 07:11:39 ON 26 JAN 2006
L2 723 S L1
L3 452268 S ANTIBOD?
L4 1 S L2 (L) L3
L5 702822 S CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?
L6 113 S L5 AND L2
L7 17 S L6 AND L3
L8 9 S L7 NOT PY>2002
L9 0 S L8 AND RITUXIMAB

FILE 'PCTFULL' ENTERED AT 07:15:47 ON 26 JAN 2006
L10 547 S GALLIUM NITRATE
L11 93747 S CANCER? OR TUMOR? OR NEOPLAS? OR LYMPHOM?
L12 52 S L10/CLM
L13 84196 S ANTIBOD?
L14 28 S L12 AND L13
L15 27 S L14 AND L11
L16 1144 S RITUXIMAB
L17 6 S L16 AND L15
L18 32952 S L13/CLM
L19 18 S L18 AND L12
L20 3 S L19 AND L16